ImageneBio (IMA) Common Equity (2020 - 2025)

ImageneBio has disclosed Common Equity across 6 years of filings, most recently posting $133.1 million for Q4 2025.

• In Q4 2025, Common Equity rose 182.92% year-over-year to $133.1 million; the TTM figure through Dec 2025 stood at $133.1 million (up 182.92% YoY), while the FY2025 annual figure was $133.1 million, up 182.92% from the prior year.
• Common Equity came in at $133.1 million for Q4 2025 at ImageneBio, down from $139.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $227.6 million in Q1 2021 to a low of -$180.4 million in Q2 2025.
• Average Common Equity over 5 years is $58.7 million, with a median of $143.4 million recorded in 2022.
• Year-over-year, Common Equity surged 434.71% in 2021 and tumbled 201.72% in 2024.
• Over 5 years, Common Equity stood at $207.9 million in 2021, then retreated by 29.3% to $147.0 million in 2022, then sank by 185.81% to -$126.1 million in 2023, then decreased by 27.32% to -$160.6 million in 2024, then jumped by 182.92% to $133.1 million in 2025.
• Per Business Quant data, the three most recent Common Equity figures were $133.1 million in Q4 2025, $139.8 million in Q3 2025, and -$180.4 million in Q2 2025.